rss
Sex Transm Infect 2008;84:29-31 doi:10.1136/sti.2007.026880
  • Chlamydia

Is new variant Chlamydia trachomatis present in England and Wales?

  1. S Alexander,
  2. C Ison
  1. Sexually Transmitted Bacteria Reference Laboratory, Health Protection Agency, Centre for Infections, London, UK
  1. Dr S Alexander, Sexually Transmitted Bacteria Reference Laboratory, Health Protection Agency, Centre for Infections, 61 Colindale Ave, London NW9 5HT, UK; Sarah.Alexander{at}hpa.org.uk
  • Accepted 26 August 2007
  • Published Online First 12 September 2007

Abstract

Background: A new variant C trachomatis (nvCT) strain has been recently isolated in Sweden, which has a 377 bp deletion in a portion of the plasmid that is the target area for some C trachomatis nucleic acid amplification tests (NAATs). Consequently, these platforms generate false negative results when presented with this strain.

Objective: To determine if nvCT is present in England and Wales.

Methods: Specimens which had been determined to be C trachomatis positive using an unaffected platform were tested for the presence of the deletion using an in-house nested PCR assay which generated a 253 bp fragment in new variant strains and a 630 bp fragment in wild-type strains. The specimens tested could be divided into two main groups: (a) 933 specimens sourced from patients attending both genitourinary medicine services and the National Chlamydia Screening Programme were forwarded from eight key laboratories within England and Wales; (b) 179 specimens were sourced from men who have sex with men and forwarded from 30 clinics throughout the UK.

Results: A total of 1112 specimens were screened for the presence of the 377 bp deletion. An in-house PCR method showed that 1066 were wild-type strains. Forty-six strains failed to generate an amplicon and were therefore untypable. This is consistent with differences in the analytical sensitivity of different NAATs and probably reflective of low C trachomatis DNA load. No nvCT strains were identified.

Conclusion: Currently, there is no evidence that nvCT is present in England and Wales. However, screening and prevalence studies are continuing and UK clinicians and microbiologists should remain vigilant for suspicious, negative results.

Footnotes

  • Both authors contributed equally to the design of this study and to the production of the manuscript.

  • Competing interests: None declared.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. sti.2007.026880v1
    2. 84/1/29 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.